DCGI approves Phase II &III trials of Oxford University vaccine

India's Case Fatality Rate drops to 2.11%

Thermo Fisher Scientific continues to expand its response to the Covid-19 pandemic, developing a new serological assay targeted towards transplant candidates
Photo by CDC on Unsplash

The Drugs Controller General of India (DCGI) has approved the Serum Institute of India, Pune, to conduct Phase II&III clinical trials of Oxford University-Astra Zeneca Covid-19 vaccine (COVISHIELD) in India. This will hasten the development of the Covid-19 vaccine.

India continues to improve the Case Fatality Rate (CFR) and maintain its global position of having one of the lowest Covid fatalities rates. With a further fall, the current CFR touched 2.11% on 3 August 2020 as per the reports. The Government claims that This is the outcome of the well-conceived and effectively implemented strategy of “Test, Track and Treat” which has guided the Covid management in the country.

The management strategy of Covid-19 also focuses on early detection and isolation of cases with seamless patient management and prioritizing care of the high-risk population using field health care workers, leading to an increase in recoveries across the country. India has seen more than 40,574 patients recovered in the last 24 hours. This takes the total recoveries to 11,86,203 and recovery rate to 65.77% amongst Covid-19 patients.

According to the press release, with improving daily recovery numbers, the gap between recovered and active cases has increased to more than 6 lakh. Presently, it is 6,06,846. This means the actual active caseload is 5,79,357, and all are under medical supervision.

Ministry of Health and Family Welfare has issued Revised Guidelines for International Arrivals in supersession of the Guidelines issued on the subject dated 24 May 2020. They will be operational from 00.01 Hrs, 8 August 2020. For further details, please click here.


Please enter your comment!
Please enter your name here